Delayed-centrifugation blood collection tube for remote blood biomarker assessment

Introduction: Plasma phosphorylated tau 217 (p-tau217) and amyloid-{beta} 42 (A{beta}42) are advancing toward clinical use for Alzheimer's disease (AD), but their reliability can be impacted by preanalytical handling. Although alternative collection tubes with distinct stabilization strategies --P100 (protease inhibitor) and HEMAcollect (hemolysis/platelet-activation minimization) --have been developed to stabilize plasma proteins, how well they preserve these markers remains unresolved; we therefore compared both against fresh standard EDTA tubes. Methods: In 40 participants, plasma p-tau217

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.